Patient access to new medicines depends heavily on coverage and reimbursement by public health insurance. In the United Kingdom and several other countries, patients face access barriers even when a medicine is covered by public health insurance because only some approved uses are reimbursed. This report examines the impact of access restrictions in public health insurance in the United Kingdom relative to France, Germany and the United States.